Roche's Atezolizumab Gets CDF Place For Bladder Cancer
Executive Summary
Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.